Clinical Trial Update: Factor IX Inhibition in Thrombosis Prevention (The FIXIT Trial) [Phase 2]

View source ↗

Summary

A Phase 2 trial by vTv Therapeutics evaluated a Factor IX inhibitor to prevent venous thromboembolism in hip fracture patients; the study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hip Fracture
• Venous Thromboembolism

Drugs mentioned

• Factor IX inhibitor (investigational) (Factor IX inhibitor)

Snippet

Sponsor: vTv Therapeutics | Conditions: Venous Thromboembolism, Embolism and Thrombosis | Phase 2 | Status: COMPLETED